Immunometabolic interactions in individuals with down syndrome across childhood, adolescence and adulthood in relation to their siblings - Scorecard - MDSpire
Advertisement
Immunometabolic interactions in individuals with down syndrome across childhood, adolescence and adulthood in relation to their siblings
Clinical Scorecard: Immunometabolic Relationships in Individuals with Down Syndrome Throughout Childhood, Adolescence, and Adulthood Compared to Their Siblings
At a Glance
Category
Detail
Condition
Down Syndrome
Key Mechanisms
Immune system dysregulation and metabolic disorders linked to cytokine dysregulation.
Target Population
Individuals with Down syndrome across all ages.
Care Setting
Clinical evaluation of immunometabolic parameters.
Key Highlights
Higher obesity rates and altered lipid profiles observed in individuals with Down syndrome.
Significantly lower levels of certain cytokines (IL-10, IL-13, IL-22) in the Down syndrome group.
Increased risk of cardiovascular disease associated with metabolic disturbances in Down syndrome.
Guideline-Based Recommendations
Diagnosis
Monitor lipid profiles and cytokine levels in individuals with Down syndrome.
Management
Implement early detection and treatment strategies for metabolic disorders in Down syndrome.
Monitoring & Follow-up
Regular assessment of obesity rates and cardiovascular risk factors in individuals with Down syndrome.
Risks
Increased risk of ischemic and hemorrhagic stroke in individuals with Down syndrome.
Patient & Prescribing Data
Individuals with Down syndrome, including children, adolescents, and adults.
Focus on managing obesity and monitoring lipid levels to reduce cardiovascular risks.
Clinical Best Practices
Conduct comprehensive metabolic and immunological evaluations in individuals with Down syndrome.
Encourage active lifestyles to mitigate obesity and associated metabolic disorders.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
